1. Home
  2. RYI vs ANAB Comparison

RYI vs ANAB Comparison

Compare RYI & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYI
  • ANAB
  • Stock Information
  • Founded
  • RYI 1842
  • ANAB 2005
  • Country
  • RYI United States
  • ANAB United States
  • Employees
  • RYI N/A
  • ANAB N/A
  • Industry
  • RYI Metal Fabrications
  • ANAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • RYI Industrials
  • ANAB Health Care
  • Exchange
  • RYI Nasdaq
  • ANAB Nasdaq
  • Market Cap
  • RYI 699.3M
  • ANAB 621.1M
  • IPO Year
  • RYI N/A
  • ANAB 2017
  • Fundamental
  • Price
  • RYI $20.61
  • ANAB $24.69
  • Analyst Decision
  • RYI Hold
  • ANAB Buy
  • Analyst Count
  • RYI 1
  • ANAB 10
  • Target Price
  • RYI $25.00
  • ANAB $49.00
  • AVG Volume (30 Days)
  • RYI 270.7K
  • ANAB 522.6K
  • Earning Date
  • RYI 07-29-2025
  • ANAB 08-12-2025
  • Dividend Yield
  • RYI 3.63%
  • ANAB N/A
  • EPS Growth
  • RYI N/A
  • ANAB N/A
  • EPS
  • RYI N/A
  • ANAB N/A
  • Revenue
  • RYI $4,439,000,000.00
  • ANAB $111,872,000.00
  • Revenue This Year
  • RYI $0.68
  • ANAB N/A
  • Revenue Next Year
  • RYI $3.13
  • ANAB $24.39
  • P/E Ratio
  • RYI N/A
  • ANAB N/A
  • Revenue Growth
  • RYI N/A
  • ANAB 387.20
  • 52 Week Low
  • RYI $17.18
  • ANAB $12.21
  • 52 Week High
  • RYI $27.41
  • ANAB $41.31
  • Technical
  • Relative Strength Index (RSI)
  • RYI 38.38
  • ANAB 45.70
  • Support Level
  • RYI $19.76
  • ANAB $23.61
  • Resistance Level
  • RYI $23.07
  • ANAB $28.50
  • Average True Range (ATR)
  • RYI 0.88
  • ANAB 1.24
  • MACD
  • RYI -0.37
  • ANAB -0.35
  • Stochastic Oscillator
  • RYI 17.60
  • ANAB 22.17

About RYI Ryerson Holding Corporation

Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. Its customers range from local, independently owned fabricators and machine shops to large, international original equipment manufacturers. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company generates substantially all of its revenue from sales of metal products. Geographically, the majority revenue is generated from the United States.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: